Prof. Dr. Mohamed E.E. Shams
Faculty of pharmacy
University of Mansoura
Prof. Mohamed E.E. Shams is a professor in Faculty of Pharmacy at the University of Mansoura in Egypt and working nowadays as a head of the Dept. of Pharmacy Practice in the School of Pharmacy, College of Health Sciences in Muscat, Oman where he teaches courses dealing with professional practice and patient care. Dr. Mohamed E.E. Shams earned his Ph.D. from the Faculties of Pharmacy and Medicine at the Johannes Gutenburg University of Mainz in Germany. His pharmacy experience includes practice in patient care, clinical pharmacogenetics, clinical pharmacokinetics, therapeutic drug monitoring, pharmacoeconomics, medications errors, drug-interactions, long-term care, and hospital settings. He has many papers and projects either presented or published in reputed journals. He is an internationally recognized expert in many areas of clinical pharmacy, pharmacy practice, and pharmaceutics.
Prof. Mohamed E.E. Shams research work focuses on therapeutic drug monitoring of psychoactive and antidepressant drugs; phenotyping and genotyping of drug metabolism to guide pharmacotherapy in psychiatry; detection of gene deletions, mutations or multiplications of metabolizing enzymes; detection of drug interactions; pharmaceutical care of patients suffering from chronic illnesses like hepatocellular carcinoma, non alcoholic steatohepatitis (NASH), and diabetes mellitus; electronic prescribing; measuring the rate of therapeutic adherence to medications, innovative medicines, technologies and approaches for improving patients’ healthcare.
1. Shams M, Hiemke C, Härtter S. Column switching and high performance liquid chromatography (HPLC) with fluorescence detection for automated analysis of venlafaxine, mirtazapine and demethylated metabolites in blood serum or plasma. 5th Workshop, Therapeutisches Drug Monitoring von Psychopharmaka (AGNP), 4-5 Juli, 2002, Magdburg- Institut für Klinische Pharmakologie, Medizinische Fakultät, Otto-von-Guericke Universität- Germany.
2. Shams M, Hiemke C, Härtter S. A rapid high-performance liquid chromatographic assay with fluorescence detection for therapeutic monitoring of the antidepressant mirtazapine, and its N-demethylated metabolite in human serum. Therapeutic Drug Monitoring 2003; 25 (4): 2003.
3. Grözinger M, Dragicevic A, Hiemke C, Shams M, Müller MJ, Härtter S. Melprone is an inhibitor of the CYP2D6 catalyzed O-demethylation of venlafaxine. Pharmacopsychiatr 2003; 36: 3-6.
4. Shams M, Hiemke C, Härtter S. Therapeutic drug monitoring of the antidepressant mirtazapine and its N-demethylated metabolite in human serum. Ther Drug Monit 2004; 26: 78-84.
5. El-Shaboury M, Gabr K, Elsayed G, Shams M. Preparation and release characteristics of indomethacin and diclofenac sodium solid-emulsion gels. Mansoura J Pharm Sci 2004; 20: 36-56.
6. Gilles M, Deuschle M, Kellner S, Shams M, Krumm B, Härtter S, Heuser I, Hiemke C. Paroxetine serum concentrations in depressed patients and response to treatment. Pharmacopsychiatr 2005; 38: 1-4.
7. Hiemke C, Dragicevic A, Kuss H, Rao M, Shams M, Müller M. TDM zur Optimierung der antidepressiven Pharmakotherapie. Die Medizinische Welt; (2005)7-8: 338-343.
8. M. E. E. Shams, B. Arneth MD PhD, C. Hiemke, PhD, A. Dragicevic M. J. Muller* PhD, R. Kaiser§ PhD, K. Lackner PhD and S. Haertter* PhD. CYP2D6 polymorphism and clinical effect of the antidepressant venlafaxine. Journal of Clinical Pharmacy and Therapeutics (2006) 31, 493–502.
9. AL-Gayyar M. M. H.*, Shams M. E. E. and Awad M. A. E. Pharmaceutical care of patients with hepatocllular carcinoma: Could GAGs be useful as a diagnostic and prognostic tumor marker? Mans.J Pharm Sci. 2007, 23, 12-26.
10. Mohamed E. E. Shams, Enaase A.M.E. Barakat, Mohammed M. H. Al-Gayyar and Maha R. Habib Impact of Lifestyle and Oxidative Stress on the Management of Patients with Type II Diabetes Mellitus. Bull. Fac. Pharm.2008, Cairo Univ.
11. Enaase A.M.E. Barakat 1, Mohammed M. H. Al-Gayyar 2 and Mohamed E. E. Shams3. Impact of diabetes and metabolic syndrome on patients with non alcoholic stetohepatitis (NASH). IXth Annual Scientific Conference of Clinical Pathology, Dept of Clinical Pathology, Dept. Faculty of Medicine -University of Mansoura, Egypt.from. 7th -8th May- 2008.
12. Abeer A. EL Fallal, Abou Bakr El Bediwi, Fouad A. El Blasy, Mohamed E. E. Shams, and Maggie R Mesbah. Influence of gentamicin sulfate on the structure and properties of glass ionomer bone cement. The 16th Alexandria International Dental Congress, October 28-31, 2008.
13. A.A. EL-Fallal, M. Shams, and O.B. Abouelatta. Effect of roughness, porosity and wettability on release of gentamnicin-loaded glass ionomer bone cement. Egyptian Dental Journal.2009,55: 625-637.
14. Arneth Borros, Shams Mohammed; Hiemke Christoph; Härtter Sebastian. Rapid and reliable genotyping procedure for detection of alleles with mutations, deletion, or/and duplication of the CYP2D6 gene. Clinical biochemistry 2009; 42 (12):1282-90.
15. Mohamed E.E. Shams. Assessing Stakeholders Satisfaction with an Electronic Prescribing Service in Various Clinical Settings. Journal of Pharmacy Research 2010, 3 (5), 1056-1060.
16. Mohamed E.E. Shams1and Enaase A.M.E. Barakat2. Measuring the Rate of Therapeutic Adherence among Outpatients with T2DM in Egypt. Saudi Journal of Pharmaceutical Science 2010; 18 (4).
17. Abd El-Gawad H. Abd El-Gawad, Osama A. Soliman, Mohamed E. E. Shams and Doaa N. Maria. Ocular Bioavailability of Triamcinolone Acetonide Complex from Different Ophthalmic Preparations in Rabbits' Eyes. Submitted to Zagazig Journal of Pharmaceutical Science and accepted.
18. Mohammed M. H. Al-Gayyar, Enaase A.M.E. Barakat, Mohamed E.E. Shams. Reactive Oxygen Species Mediate Nonalcoholic Fatty Liver Injury Through TNF- α: Relation to BodyWeight. Mansoura Journal of Pharmaceutical Sciences,2010, 1-6.
19. Mohammed. E. E. Shams, Mohammed M. H. Al-Gayyar, Enaase A.M.E. Barakat. Type 2 Diabetes Mellitus-Induced Hyperglycemia in Patients with NAFLD and Normal LFTs: Relationship to Lipid Profile, Oxidative Stress and Pro-Inflammatory Cytokines. Sci Pharm. 2011; in press. doi:10.3797/scipharm.1104-21
20. Mohamed E.E. Shams. Implementation of an e-prescribing service: Users’ satisfaction and recommendations. Canadian Pharmacists Journal (C P J / R P C) • J U L Y / A U G U S T 2 0 1 1 • V O L 1 4 4 , N O 4
21. Mohamed E. E. Shams, Mohammed M. H. Al-Gayyar,Enaase A. M. E. Barakat, Mohamed A. Ebrahim, Mamdouh M. El-Shishtawy. Circulating adiponectin: a potential prognostic marker for hepatocellular carcinoma. Chinese-German Journal of Clinical Oncology. October 2011, Vol. 10, No. 10, P570–P574. DOI 10.1007/s10330-011-0859-7.
22. MMH Al-Gayyar, MEE Shams, EAME Barakat. Fish oil improves lipid metabolism and ameliorates inflammation in patients with metabolic syndrome: impact of nonalcoholic fatty liver disease. Pharmaceutical biology, 2012, 50 (3), 297-303
23. MEE Shams. Innovative Medicines, technologies and approaches for improving patients’ healthcare. World Journal of Pharmaceutical Sciences, 2013, 1 (4), 156- 162
24. Mohamed EE Shams, Wael M. Gabr, Enaase A. M. E. Barakat. Effect of Fasting during Ramadan on Migraine Sufferers. Journal of Behavioral and Brain Science, 2013, 3, 373-378
25. C Hiemke, M Shams. Phenotyping and genotyping of drug metabolism to guide pharmacotherapy in psychiatry. Current drug delivery, 2013, 10 (1), 46-53
26. MMH Al-Gayyar, A Al Youssef, IO Sherif, MEE Shams, A Abbas. Protective effects of arjunolic acid against cardiac toxicity induced by oral sodium nitrite: effects on cytokine balance and apoptosis. Life sciences, 2014, 111 (1), 18-26
27. WM Gabr, MEE Shams. Adherence to medication among outpatient adolescents with epilepsy. Saudi Pharmaceutical Journal, 2015, 23 (1), 33-40
28. G Hefner, S Unterecker, MEE Shams, M Wolf, T Falter, E Haen, C Hiemke. Melperone but not bisoprolol or metoprolol is a clinically relevant inhibitor of CYP2D6: evidence from a therapeutic drug monitoring survey. Journal of Neural Transmission, 2015, 122 (11), 1609-1617
29. G Hefner, MEE Shams, S Unterecker, T Falter, C Hiemke. Retrospective pilot study for analysis of antidepressant serum concentrations of citalopram and venlafaxine during inflammation. Pharmacopsychiatry, 2015, 25 (06), 215-218
30. G Hefner, MEE Shams, S Unterecker, T Falter, C Hiemke. Inflammation and psychotropic drugs: the relationship between C-reactive protein and antipsychotic drug levels. G Hefner, MEE Shams, S Unterecker, T Falter, C Hiemke. Psychopharmacology, 2016, 233 (9), 1695-1705